about
Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/lStimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infectionGenetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association studyFailure to detect xenotropic murine leukemia virus-related virus in blood of individuals at high risk of blood-borne viral infectionsPhylogenetic approach reveals that virus genotype largely determines HIV set-point viral loadDeterminants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapyThe individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patientsEarly antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruptionRisk of influenza-like illness in an acute health care setting during community influenza epidemics in 2004-2005, 2005-2006, and 2006-2007: a prospective study.Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine.Ecthyma Gangrenosum: Escherichia coli or Pseudomonas aeruginosa?Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB™) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infectionMolecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland.A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA.A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDSHuman immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy.Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study.Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection.Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy.Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy.Micro-structural brain alterations in aviremic HIV+ patients with minor neurocognitive disorders: a multi-contrast study at high field.Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque.HIV treatment for preventionEstimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance.Increased mortality after a first myocardial infarction in human immunodeficiency virus-infected patients; a nested cohort study.Supervised interruptions of antiretroviral therapy.Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort studyKidney light chain disease in patients with the acquired immunodeficiency syndrome.Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo.Structured treatment interruptions in HIV infection: benefit or disappointment?Interrupting highly active antiretroviral therapy in patients with HIV.Increased incidence of sexually transmitted infections in Geneva, Switzerland.Immunological recovery and antiretroviral therapy in HIV-1 infection.HIV rebounds from latently infected cells, rather than from continuing low-level replicationLate presentation of HIV-infected individuals.
P50
Q21128672-727C1975-1768-4446-A6DE-9843C56CCD59Q24536249-1C0ECD5D-A0EB-42A8-BF11-DBDCE5C92C41Q28269827-8DD90E05-1492-4DC6-A826-6315D6824E9FQ28295313-0B190D14-E4AE-4BAA-A157-BC101037FEB9Q28475652-644F42ED-FA44-4857-85D9-117C7109BF57Q28478666-8400B103-5A65-483E-893E-4FEEFEB4912DQ28536153-A246F286-3D64-4FBD-BE4F-D226E1F711B0Q28742727-DAA0E010-B400-4ABC-8147-296FD295262BQ30398938-07169372-17E3-4C7F-ABCB-D55052C79A81Q30419842-79C04983-5EB3-448C-B482-8D08F4317555Q33736497-D25C89D4-EEDC-4C09-98C6-DA71CE5058C1Q33883813-29022521-209D-424A-A75B-6F91D03C0A04Q34075008-1E5F8C21-0859-43DD-B36C-EDA021A3359DQ34109639-31B0E919-6C52-4D1E-87A2-5311C1ADC86CQ34113502-873AFFFE-F271-4A89-ADE0-FF2D124AFE2CQ34127697-D539CE25-7D48-455E-AF1A-771FD84FB445Q34269641-D7EA11FC-FA4F-4637-B997-3E346B64C7B3Q34339925-87A53327-37D2-49B1-ADBA-6B4714826EC1Q34348075-FAEE82F7-FC4D-4BAC-886A-E548C5246560Q34547116-BAC61482-D4AC-47B4-8076-940767062557Q34597895-9EB7A968-1885-4A44-9C71-B9A6FB5BA192Q34699175-83851B9F-5AE1-4431-A97E-5F5F28B6EE8BQ34761540-F3B7C166-5E59-4218-BB80-06C4FC062550Q34763589-2BE16161-B2DE-4078-B7D9-A6B33D6FD6E2Q34772825-02788160-ACF4-4414-A543-C684FE034C48Q34988471-F01DF593-48A3-4DDA-AA11-C9B315AF7907Q35015712-E9ECA813-F3F9-4A31-A54B-577379149801Q35069410-E50FC3AF-A801-437F-8263-53F80E72CACAQ35083980-F4AE7632-64DF-4D2D-B788-F7DC2C71EC38Q35107777-C831527B-EDCE-4E2C-AAC4-F7A4097E5AA1Q35108735-708F52EF-761E-406F-9CED-08E7A68F651DQ35113120-D43D3F86-4C8A-4D78-9EC0-70BF2CA92612Q35452267-5092FFDB-3865-476A-9186-EB69F1F09924Q35778972-1F11D167-5E01-4FF8-AF29-67B425F1C18FQ35917152-FCAA3DEC-0A58-426A-9E52-31DC8A32AB31Q36066209-F95EE479-8815-42C7-8B2C-DDCD485FD45BQ36327523-9B06044B-F57B-4976-AB0B-148BC43A110EQ36456559-B913C846-D878-4F10-8EB3-F04F7C5A9F16Q36954950-13CA48D8-1816-494E-8CEC-795BD588D82AQ36966856-7DFD50A1-8AFD-4B49-B554-A18C711715A9
P50
name
Bernard Hirschel
@ast
Bernard Hirschel
@en
Bernard Hirschel
@nl
type
label
Bernard Hirschel
@ast
Bernard Hirschel
@en
Bernard Hirschel
@nl
prefLabel
Bernard Hirschel
@ast
Bernard Hirschel
@en
Bernard Hirschel
@nl
P214
P214
P31
P7859
lccn-n88620685